BACKGROUND: Prostate-specific antigen (PSA) is a pivotal downstream target gene of the androgen receptor (AR), and a serum biomarker to monitor prostate cancer (PrCa) progression. It has been reported that PSA transactivates AR, but the mechanistic requirements of this response have not been investigated. METHODS: We studied the localization of PSA, AR, and Src in intracellular compartments of synthetic androgen (R1881)-stimulated LNCaP and C4-2B PrCa cells, using immunofluorescence and subcellular fractionation approaches. We also investigated the effect of downregulation of PSA on AR expression by immunoblotting and real-time PCR using short hairpin RNA (shRNA) and small interfering RNA (siRNA). Src activity was analyzed by immunoblotting. RESULTS: R1881 stimulation induced nuclear localization of both PSA and AR in LNCaP and C4-2B PrCa cells as well as increased phosphorylation of Src. Stable shRNA or transient siRNA knockdown of PSA resulted in reduced AR protein levels as well as AR mRNA levels in C4-2B cells. Similar to C4-2B cells, ablation of AR levels upon silencing of PSA was also confirmed in VCaP cells, another androgen-independent cell line. Silencing of PSA did not cause significant changes in Src activation; besides, Src regulation by integrins did not appear to affect AR transcriptional activity. CONCLUSIONS: PSA localizes to nuclei of androgen-stimulated PrCa cells, and controls AR mRNA and protein levels. This regulatory loop is specific for PSA, does not involve known AR activators such as Src and AKT, and may contribute to AR signaling under conditions of increasing PSA levels in patients.
BACKGROUND:Prostate-specific antigen (PSA) is a pivotal downstream target gene of the androgen receptor (AR), and a serum biomarker to monitor prostate cancer (PrCa) progression. It has been reported that PSA transactivates AR, but the mechanistic requirements of this response have not been investigated. METHODS: We studied the localization of PSA, AR, and Src in intracellular compartments of synthetic androgen (R1881)-stimulated LNCaP and C4-2B PrCa cells, using immunofluorescence and subcellular fractionation approaches. We also investigated the effect of downregulation of PSA on AR expression by immunoblotting and real-time PCR using short hairpin RNA (shRNA) and small interfering RNA (siRNA). Src activity was analyzed by immunoblotting. RESULTS: R1881 stimulation induced nuclear localization of both PSA and AR in LNCaP and C4-2B PrCa cells as well as increased phosphorylation of Src. Stable shRNA or transient siRNA knockdown of PSA resulted in reduced AR protein levels as well as AR mRNA levels in C4-2B cells. Similar to C4-2B cells, ablation of AR levels upon silencing of PSA was also confirmed in VCaP cells, another androgen-independent cell line. Silencing of PSA did not cause significant changes in Src activation; besides, Src regulation by integrins did not appear to affect AR transcriptional activity. CONCLUSIONS:PSA localizes to nuclei of androgen-stimulated PrCa cells, and controls AR mRNA and protein levels. This regulatory loop is specific for PSA, does not involve known AR activators such as Src and AKT, and may contribute to AR signaling under conditions of increasing PSA levels in patients.
Authors: James Gulley; Alice P Chen; William Dahut; Philip M Arlen; Anne Bastian; Seth M Steinberg; Kwong Tsang; Dennis Panicali; Diane Poole; Jeffrey Schlom; J Michael Hamilton Journal: Prostate Date: 2002-10-01 Impact factor: 4.104
Authors: Li-Fen Lee; Maggie C Louie; Sonal J Desai; Joy Yang; Hong-Wu Chen; Christopher P Evans; Hsing-Jien Kung Journal: Oncogene Date: 2004-03-18 Impact factor: 9.867
Authors: Di Wen; Deepak Chitkara; Hao Wu; Michael Danquah; Renukadevi Patil; Duane D Miller; Ram I Mahato Journal: Pharm Res Date: 2014-05-02 Impact factor: 4.200
Authors: Matthias Saar; Hongjuan Zhao; Rosalie Nolley; Sarah R Young; Ilsa Coleman; Peter S Nelson; Robert L Vessella; Donna M Peehl Journal: Cancer Lett Date: 2014-07-03 Impact factor: 8.679
Authors: Huimin Lu; Tao Wang; Jing Li; Carmine Fedele; Qin Liu; Jianzhong Zhang; Zhong Jiang; Dhanpat Jain; Renato V Iozzo; Shelia M Violette; Paul H Weinreb; Roger J Davis; Daniel Gioeli; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino Journal: Cancer Res Date: 2016-07-22 Impact factor: 12.701
Authors: Shaneabbas Raza; Megan Meyer; Jared Schommer; Kimberly D P Hammer; Bin Guo; Othman Ghribi Journal: Med Oncol Date: 2016-01-05 Impact factor: 3.064
Authors: Thirupandiyur S Udayakumar; Radka Stoyanova; Mohammed M Shareef; Zhaomei Mu; Sakhi Philip; Kerry L Burnstein; Alan Pollack Journal: Mol Cancer Ther Date: 2016-03-04 Impact factor: 6.261
Authors: Avital Lev; Amriti R Lulla; Brian C Ross; Marie D Ralff; Petr B Makhov; David T Dicker; Wafik S El-Deiry Journal: Mol Cancer Res Date: 2018-03-27 Impact factor: 5.852